{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.8274","value":"518.167"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"657.4978","value":"1241.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)"}],"paramType":"MEAN","populationDescription":"PK-Evaluable Population was defined as participants in the safety lead-in cohort who have sufficient dosing data and ixazomib concentration-time data to permit calculation of PK parameters. Number analyzed is the number of participants with data available for analysis at the given time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 15 predose and at multiple timepoints (up to 168 hours) postdose","title":"AUCtau: Area Under the Concentration-time Curve During a Dosing Interval for Ixazomib in RRMM Participants","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}